Axovant Sciences (AXON) Trading Up 8.3%
Axovant Sciences Ltd (NASDAQ:AXON) shares were up 8.3% during mid-day trading on Tuesday . The stock traded as high as $2.11 and last traded at $2.09. Approximately 694,453 shares changed hands during mid-day trading, a decline of 76% from the average daily volume of 2,952,514 shares. The stock had previously closed at $1.93.
Several research analysts have issued reports on AXON shares. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Axovant Sciences in a report on Monday, August 13th. Zacks Investment Research raised shares of Axovant Sciences from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a report on Thursday, July 12th. Jefferies Financial Group lifted their target price on shares of Axovant Sciences from $3.00 to $5.00 and gave the stock a “hold” rating in a report on Monday, June 11th. BidaskClub raised shares of Axovant Sciences from a “strong sell” rating to a “sell” rating in a report on Saturday, September 1st. Finally, Chardan Capital reaffirmed a “hold” rating and issued a $4.00 target price on shares of Axovant Sciences in a report on Wednesday, June 6th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the stock. Axovant Sciences currently has an average rating of “Hold” and an average price target of $11.70.
The company has a current ratio of 2.34, a quick ratio of 2.34 and a debt-to-equity ratio of 1.48.
In related news, Director George Bickerstaff purchased 25,000 shares of Axovant Sciences stock in a transaction dated Thursday, August 9th. The stock was purchased at an average cost of $2.07 per share, for a total transaction of $51,750.00. Following the completion of the purchase, the director now directly owns 50,000 shares of the company’s stock, valued at approximately $103,500. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 6.00% of the company’s stock.
Several hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC grew its stake in shares of Axovant Sciences by 1,627.0% in the second quarter. Tower Research Capital LLC TRC now owns 62,139 shares of the biotechnology company’s stock worth $141,000 after acquiring an additional 58,541 shares during the period. Paloma Partners Management Co bought a new stake in Axovant Sciences during the second quarter valued at approximately $356,000. GSA Capital Partners LLP bought a new stake in Axovant Sciences during the second quarter valued at approximately $338,000. Connor Clark & Lunn Investment Management Ltd. grew its position in Axovant Sciences by 183.1% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 495,450 shares of the biotechnology company’s stock valued at $1,120,000 after buying an additional 320,450 shares during the period. Finally, Millennium Management LLC grew its position in Axovant Sciences by 175.6% during the first quarter. Millennium Management LLC now owns 1,330,910 shares of the biotechnology company’s stock valued at $1,770,000 after buying an additional 847,946 shares during the period. Hedge funds and other institutional investors own 9.38% of the company’s stock.
About Axovant Sciences (NASDAQ:AXON)
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease.
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.